| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Henry Nasrallah, David Walling, Peter J Weiden, Yangchun Du, Baiyun Yao, Sergey Yagoda, Amy Claxto. Aripiprazole Lauroxil 2-Month Formulation With 1-Day Initiation for Acute Schizophrenia: ALPINE Exploratory Efficacy and Patient-Reported Outcomes. CNS spectrums. vol 26. issue 2. 2021-07-23. PMID:34127096. |
the randomized, controlled, phase 3b alpine study evaluated efficacy and safety of a 2-month formulation of aripiprazole lauroxil (al) initiated with a 1-day regimen during hospitalization for an acute exacerbation of schizophrenia; paliperidone palmitate (pp) was included as an active control. |
2021-07-23 |
2023-08-13 |
Not clear |
| Lakshmi Priya, Bini Moorth. A Case of Hypersexuality in a Patient Receiving Aripiprazole for Schizophrenia. Case reports in psychiatry. vol 2021. 2021-07-15. PMID:34258097. |
a case of hypersexuality in a patient receiving aripiprazole for schizophrenia. |
2021-07-15 |
2023-08-13 |
Not clear |
| Lakshmi Priya, Bini Moorth. A Case of Hypersexuality in a Patient Receiving Aripiprazole for Schizophrenia. Case reports in psychiatry. vol 2021. 2021-07-15. PMID:34258097. |
the case presented is of a 24-year-old male with schizophrenia who developed hypersexuality symptoms after initiation of aripiprazole. |
2021-07-15 |
2023-08-13 |
Not clear |
| Yasin Hasan Balcioglu, Hasan Gokcay, Umit Haluk Yesilkay. One Plus One Sometimes Equals More Than Two: Long-acting Injectable Aripiprazole Adjunction in Clozapine-Resistant Schizophrenia. Clinical neuropharmacology. vol 43. issue 5. 2021-07-08. PMID:32947430. |
one plus one sometimes equals more than two: long-acting injectable aripiprazole adjunction in clozapine-resistant schizophrenia. |
2021-07-08 |
2023-08-13 |
Not clear |
| Yasin Hasan Balcioglu, Hasan Gokcay, Umit Haluk Yesilkay. One Plus One Sometimes Equals More Than Two: Long-acting Injectable Aripiprazole Adjunction in Clozapine-Resistant Schizophrenia. Clinical neuropharmacology. vol 43. issue 5. 2021-07-08. PMID:32947430. |
although we cannot postulate on a single exact mechanism for the increased efficacy of clozapine and aripiprazole combination, we may suggest that, at least for a subgroup of patients with schizophrenia who respond clinically to clozapine at a suboptimal level, combination with aripiprazole may be an effective therapeutic strategy. |
2021-07-08 |
2023-08-13 |
Not clear |
| Association of Aripiprazole With Reduced Hippocampal Atrophy During Maintenance Treatment of First-Episode Schizophrenia: Erratum. Journal of clinical psychopharmacology. vol 41. issue 4. 2021-06-29. PMID:34181366. |
association of aripiprazole with reduced hippocampal atrophy during maintenance treatment of first-episode schizophrenia: erratum. |
2021-06-29 |
2023-08-13 |
Not clear |
| Xiaoshuai Ning, Lei Xia, Yudong Shi, Rui Hao, Feng Geng, Kai Zhang, Huanzhong Li. Cognitive improvement function of aripiprazole in adolescents with first-episode and repeated-episode schizophrenia. Asian journal of psychiatry. vol 58. 2021-06-21. PMID:33611084. |
cognitive improvement function of aripiprazole in adolescents with first-episode and repeated-episode schizophrenia. |
2021-06-21 |
2023-08-13 |
Not clear |
| Pedro Such, José Manuel Olivares, Lizbeth Arias, Mette Troels Berg, Jessica Mader. Online Survey of Clinical Practice in Patients with Schizophrenia Treated with Long-Acting Injectable Aripiprazole or Paliperidone Palmitate. Neuropsychiatric disease and treatment. vol 17. 2021-06-19. PMID:34140772. |
online survey of clinical practice in patients with schizophrenia treated with long-acting injectable aripiprazole or paliperidone palmitate. |
2021-06-19 |
2023-08-13 |
Not clear |
| Lavjot Kaur, V R Sinh. Long Acting Polycaprolactone Based Parenteral Formulation of Aripiprazole Targeting Behavioural and Biochemical Deficit in Schizophrenia. Journal of pharmaceutical sciences. vol 110. issue 5. 2021-06-17. PMID:33383057. |
long acting polycaprolactone based parenteral formulation of aripiprazole targeting behavioural and biochemical deficit in schizophrenia. |
2021-06-17 |
2023-08-13 |
rat |
| b' Vjekoslav Peitl, Mario \\xc5\\xa0tefanovi\\xc4\\x87, Ivona Orlovi\\xc4\\x87, Jelena Culej, Ana Renduli\\xc4\\x87, Krunoslav Mate\\xc5\\xa1i\\xc4\\x87, Dalibor Karlovi\\xc4\\x8. Long acting aripiprazole influences cognitive functions in recent onset schizophrenia. Psychopharmacology. vol 238. issue 6. 2021-06-01. PMID:33580813.' |
long acting aripiprazole influences cognitive functions in recent onset schizophrenia. |
2021-06-01 |
2023-08-13 |
Not clear |
| b' Vjekoslav Peitl, Mario \\xc5\\xa0tefanovi\\xc4\\x87, Ivona Orlovi\\xc4\\x87, Jelena Culej, Ana Renduli\\xc4\\x87, Krunoslav Mate\\xc5\\xa1i\\xc4\\x87, Dalibor Karlovi\\xc4\\x8. Long acting aripiprazole influences cognitive functions in recent onset schizophrenia. Psychopharmacology. vol 238. issue 6. 2021-06-01. PMID:33580813.' |
beneficial effects of aripiprazole on cognition in schizophrenia have been previously reported, but not in recent onset schizophrenia. |
2021-06-01 |
2023-08-13 |
Not clear |
| Chi-Un Pae, Changsu Han, Won-Myong Bahk, Soo-Jung Lee, Ashwin A Patkar, Prakash S Masan. Clinical Benefit and Utility of Switching to Aripiprazole Once Monthly in Patients with Antipsychotic Polypharmacy or Long Acting Injectable Antipsychotics for Patients with Schizophrenia in Routine Practice: A Retrospective, Observation Study. Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology. vol 19. issue 2. 2021-06-01. PMID:33888652. |
clinical benefit and utility of switching to aripiprazole once monthly in patients with antipsychotic polypharmacy or long acting injectable antipsychotics for patients with schizophrenia in routine practice: a retrospective, observation study. |
2021-06-01 |
2023-08-13 |
Not clear |
| Chi-Un Pae, Changsu Han, Won-Myong Bahk, Soo-Jung Lee, Ashwin A Patkar, Prakash S Masan. Clinical Benefit and Utility of Switching to Aripiprazole Once Monthly in Patients with Antipsychotic Polypharmacy or Long Acting Injectable Antipsychotics for Patients with Schizophrenia in Routine Practice: A Retrospective, Observation Study. Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology. vol 19. issue 2. 2021-06-01. PMID:33888652. |
in a number of controlled clinical trials and naturalistic studies, aripiprazole once monthly (aom) has been found to be effective and safe as acute and maintenance treatment options for schizophrenia. |
2021-06-01 |
2023-08-13 |
Not clear |
| David D Kim, Alasdair M Barr, Lulu Lian, Jessica W Y Yuen, Diane Fredrikson, William G Honer, Allen E Thornton, Ric M Procyshy. Efficacy and tolerability of aripiprazole versus D NPJ schizophrenia. vol 7. issue 1. 2021-05-29. PMID:34035313. |
efficacy and tolerability of aripiprazole versus d early intervention is essential for favorable long-term outcomes in schizophrenia. |
2021-05-29 |
2023-08-13 |
Not clear |
| Javier Labad, Itziar Montalvo, Alexandre González-Rodríguez, Clemente García-Rizo, Benedicto Crespo-Facorro, José Antonio Monreal, Diego Pala. Pharmacological treatment strategies for lowering prolactin in people with a psychotic disorder and hyperprolactinaemia: A systematic review and meta-analysis. Schizophrenia research. vol 222. 2021-05-18. PMID:32507371. |
our study suggests that, in terms of levels of evidence, adding aripiprazole is the first option to be considered for lowering prolactin concentrations in patients with schizophrenia and hyperprolactinaemia. |
2021-05-18 |
2023-08-13 |
Not clear |
| Seokmin Noh, Euihyeon Na, Se Jin Park, Seok Hyeon Kim, A Eden Evins, Sungwon Ro. Effects of various antipsychotics on driving-related cognitive performance in adults with schizophrenia. Journal of psychiatric research. vol 131. 2021-05-14. PMID:32971359. |
in this cross-sectional design study, adults with schizophrenia treated with aripiprazole or paliperidone antipsychotic monotherapy demonstrated superior driving-related cognitive performance than those treated with haloperidol or risperidone antipsychotic monotherapy. |
2021-05-14 |
2023-08-13 |
human |
| Joseph P McEvoy, Peter J Weiden, Paul H Lysaker, Xiaowu Sun, Amy K O'Sulliva. Long-term effect of aripiprazole lauroxil on health-related quality of life in patients with schizophrenia. BMC psychiatry. vol 21. issue 1. 2021-04-26. PMID:33761928. |
long-term effect of aripiprazole lauroxil on health-related quality of life in patients with schizophrenia. |
2021-04-26 |
2023-08-13 |
Not clear |
| Joseph P McEvoy, Peter J Weiden, Paul H Lysaker, Xiaowu Sun, Amy K O'Sulliva. Long-term effect of aripiprazole lauroxil on health-related quality of life in patients with schizophrenia. BMC psychiatry. vol 21. issue 1. 2021-04-26. PMID:33761928. |
this post hoc analysis of clinical trial data evaluated long-term, self-reported mental and physical health-related quality of life (hrqol) scores in schizophrenia patients receiving aripiprazole lauroxil (al), an atypical long-acting injectable (lai) antipsychotic approved for the treatment of schizophrenia in adults. |
2021-04-26 |
2023-08-13 |
Not clear |
| Ping Jiang, Xiujia Sun, Juanjuan Ren, Hongmei Liu, Zhiguang Lin, Junwen Liu, Xinyu Fang, Chen Zhan. Effects of the combination of second-generation antipsychotics on serum concentrations of aripiprazole and dehydroaripiprazole in Chinese patients with schizophrenia. General psychiatry. vol 34. issue 2. 2021-04-16. PMID:33851072. |
effects of the combination of second-generation antipsychotics on serum concentrations of aripiprazole and dehydroaripiprazole in chinese patients with schizophrenia. |
2021-04-16 |
2023-08-13 |
Not clear |
| Ping Jiang, Xiujia Sun, Juanjuan Ren, Hongmei Liu, Zhiguang Lin, Junwen Liu, Xinyu Fang, Chen Zhan. Effects of the combination of second-generation antipsychotics on serum concentrations of aripiprazole and dehydroaripiprazole in Chinese patients with schizophrenia. General psychiatry. vol 34. issue 2. 2021-04-16. PMID:33851072. |
aripiprazole (ari) is often prescribed alone or in combination with other second-generation antipsychotics (sgas) to treat patients with schizophrenia. |
2021-04-16 |
2023-08-13 |
Not clear |